The adverse biology of MDS with SRSF2 mutations could be associated with the altered splicing of genes such as EZH2 [45] and their implications in DNA damage accumulation through alterations of the P53 function [46]. This evidence concerns the gene TP53 and myelodysplastic syndrome.